Barclays PLC Buys 5,367 Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)

Barclays PLC grew its holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) by 325.1% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,018 shares of the company’s stock after buying an additional 5,367 shares during the quarter. Barclays PLC’s holdings in Telomir Pharmaceuticals were worth $45,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in Telomir Pharmaceuticals during the 2nd quarter valued at $241,000. Beaird Harris Wealth Management LLC boosted its stake in Telomir Pharmaceuticals by 212.9% during the 2nd quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock worth $70,000 after acquiring an additional 9,950 shares during the last quarter. Suncoast Equity Management increased its position in shares of Telomir Pharmaceuticals by 109.9% in the 3rd quarter. Suncoast Equity Management now owns 51,194 shares of the company’s stock valued at $329,000 after buying an additional 26,803 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Telomir Pharmaceuticals by 99.1% in the third quarter. State Street Corp now owns 36,094 shares of the company’s stock worth $232,000 after acquiring an additional 17,967 shares in the last quarter.

Telomir Pharmaceuticals Price Performance

Shares of TELO stock opened at $4.30 on Friday. Telomir Pharmaceuticals, Inc. has a 12-month low of $3.11 and a 12-month high of $20.72. The firm has a fifty day moving average of $4.57 and a 200-day moving average of $4.75.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.